Four leading drugmakers were back in federal court on Thursday to challenge the constitutionality of the Medicare Drug Price Negotiation Program under the Inflation Reduction Act.

Bristol Myers Squibb, Novo Nordisk, Novartis and Johnson & Johnson presented their arguments to Judge Zahid N. Quraishi of the U.S. District Court for the District of New Jersey. This hearing was different from the others in that the court allowed the four companies to present their oral arguments in a single session.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.